MARLBOROUGH, Mass.,
Feb. 5, 2018 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company
developing immuno-oncology therapeutics based on its
self-delivering RNAi (sd-rxRNA®) therapeutic platform today
announced that it will give a webcast presentation at the BIO CEO
and Investor Conference. RXi's President and CEO, Dr. Geert Cauwenbergh, will highlight the Company's
therapeutic platform and its business strategy to advance the
development of a new class of cancer therapeutics, using adoptive
cell transfer (ACT).
Title: Developing
Self-Delivering RNAi (sd-rxRNA®) for Immuno-oncology
Track and location: Oncology, Room: Odets
Date and Time: Monday, February
12, 2018, 2:15 pm ET
Presenter: Dr. Geert
Cauwenbergh, President and CEO
Logo -
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
Now in its 20th year, the BIO CEO & Investor Conference is
one of the largest investor conferences focused on established and
emerging publicly traded and select private biotech
companies. The conference will take place February 12-13, 2018 at the New York Marriott
Marquis in New York City.
The link for the webcast may be found on the Company's website
under the "Investors – Events and Presentations" section
at www.rxipharma.com.
About RXi's self-delivering RNAi (sd-rxRNA) technology
platform
sd-rxRNA, RXi's proprietary self-delivering RNAi platform, is a
single chemically modified compound with delivery and therapeutic
properties built directly into the compound itself. The compound is
asymmetrical with a phosphorothioate backbone and contains chemical
modifications that provide for efficient cellular uptake and gene
silencing. These compounds are potent, stable and specific, and
demonstrated to be safe and active in a clinical setting.
RXi's novel sd-rxRNA technology differs from natural and most
synthetic RNA interference (RNAi) molecules in that they are
chemically modified to allow for efficient internalization of the
compounds by cells and silencing of the targeted genes.
Importantly, unlike other naked siRNA compounds, delivery of
sd-rxRNAs are not limited to a specific cell type. For local
delivery and ex vivo cell-based therapeutic applications,
our compounds do not require delivery vehicles. This is a major
advantage since delivery vehicles can have related toxicity that
affects cell viability. sd-rxRNA has demonstrated nearly 100
percent transfection efficiency with high cell viability in
numerous cell types.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology
company developing immuno-oncology therapeutics based on its
self-delivering RNAi (sd-rxRNA®) therapeutic platform.
Building on the pioneering discovery of RNAi, scientists at
RXi have harnessed the naturally occurring RNAi process which can
be used to "silence" or down-regulate the expression of a specific
gene that may be overexpressed in a disease condition. RXi
developed a robust RNAi therapeutic platform, including sd-rxRNA
compounds, that has the potential to highly selectively block the
expression of any target in the genome, thus providing
applicability to many therapeutic areas. RXi's extensive
patent portfolio provides for multiple product and business
development opportunities across a broad spectrum of therapeutic
areas, and we actively pursue research collaborations, partnering
and out-licensing opportunities with academia and pharmaceutical
companies. For additional information, visit the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™,
RXI-762, RXI-804 and our other product candidates (collectively
"our product candidates"); the future success of our clinical
trials with our product candidates; the timing for the commencement
and completion of clinical trials; our ability to enter into
strategic partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-bio-ceo-and-investor-conference-300593157.html
SOURCE RXi Pharmaceuticals Corporation